200 related articles for article (PubMed ID: 26169212)
1. Adverse Effects Associated With Newer Diabetes Therapies.
Akiyode OF; Adesoye AA
J Pharm Pract; 2017 Apr; 30(2):238-244. PubMed ID: 26169212
[TBL] [Abstract][Full Text] [Related]
2. Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.
Freeman J
J Fam Pract; 2015 Dec; 64(12 Suppl):S59-66. PubMed ID: 26845016
[TBL] [Abstract][Full Text] [Related]
3. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kuhn A; Park J; Ghazi A; Aroda VR
Curr Cardiol Rep; 2017 Mar; 19(3):25. PubMed ID: 28251513
[TBL] [Abstract][Full Text] [Related]
4. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
5. Making sense of newer treatment options for type 2 diabetes.
Lee PC; Hare MJL; Bach LA
Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
8. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
DeFilippis EM; Givertz MM
Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
Yassin SA; Aroda VR
Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
[TBL] [Abstract][Full Text] [Related]
10. [Management of Type 2 Diabetes: a Practical Approach].
Donath M
Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
[TBL] [Abstract][Full Text] [Related]
11. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Madsbad S; Krarup T; Deacon CF; Holst JJ
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
[TBL] [Abstract][Full Text] [Related]
13. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
14. Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy.
Vaughan EM; Santiago-Delgado ZM
Am Fam Physician; 2024 Apr; 109(4):333-342. PubMed ID: 38648832
[TBL] [Abstract][Full Text] [Related]
15. Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes.
Bilal A; Pratley RE
Endocrinol Metab Clin North Am; 2023 Jun; 52(2):355-375. PubMed ID: 36948784
[TBL] [Abstract][Full Text] [Related]
16. [New pharmacological treatment methods of type 2 diabetes].
Madsbad S; Hermansen K
Ugeskr Laeger; 2012 Sep; 174(37):2143-6. PubMed ID: 22971293
[TBL] [Abstract][Full Text] [Related]
17. Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.
Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
Diabet Med; 2020 Apr; 37(4):648-656. PubMed ID: 31692117
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
19. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
20. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
Russell-Jones D
Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
